Metagenomi, Inc. Common Stock (MGX) Stock Forecast & Price Target
Metagenomi, Inc. Common Stock · NASDAQ
$1.20-0.01 (-0.83%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Metagenomi, Inc. Common Stock, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $5.00 to $9.00, a moderate spread. The average target of $7.00 sits 483% above the current $1.20. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.50 next quarter toward $-2.12 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Metagenomi, Inc. Common Stock.
As of Jul, 3 of 3 firms rate MGX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
MGX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.50
Range $-0.53 – $-0.47 · 3 analysts · -8% YoY
Next period, 3 analysts expect Metagenomi, Inc. Common Stock to earn $-0.50 a share (range $-0.53 – $-0.47), versus $-0.55 a year earlier. Full-year consensus is $-2.16, growing to $-2.12 the year after.
REVENUE · NEXT QUARTER
$3.5M
Range $2.3M – $5.0M · 3 analysts · -60% YoY
Revenue is expected to reach $3.5M (range $2.3M – $5.0M), -60.2% year-over-year. Full-year consensus is $10.2M, rising to $11.2M next year.
Top analysts covering Metagenomi, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MGX.
#1
Keay Nakae
Chardan Capital · Rank #130
Buy
$5.00+316.7% to target
Overall win rate
41%
+ Follow
#2
Mitchell Kapoor
HC Wainwright & Co. · Rank #165
Buy
$7.00+483.3% to target
Overall win rate
34%
+ Follow
#3
Yanan Zhu
Wells Fargo
Buy
$9.00+650.0% to target
Coverage
—
+ Follow
MGX stock forecast FAQ
What is MGX's average 12-month price target?+
The 2 analysts with a live target average $7.00 for Metagenomi, Inc. Common Stock over the next 12 months, ranging from a $9.00 high to a $5.00 low.
Is MGX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for MGX?+
The Street-high target is $9.00 (Wells Fargo), and the Street-low is $5.00 (Chardan Capital). The average of all 2 active targets is $7.00.
How many Wall Street analysts cover MGX?+
3 analysts have an active rating on Metagenomi, Inc. Common Stock, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering MGX?+
Among analysts who currently cover MGX, Keay Nakae of Chardan Capital has the strongest overall Quantellect track record (Rank #130). Their current call is Buy with a $5.00 target.
What is Metagenomi, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.50 per share (range $-0.53 – $-0.47) across 3 analysts. Full-year EPS is projected at $-2.16, rising to $-2.12 the following year.
How much revenue is Metagenomi, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $3.5M (range $2.3M – $5.0M). Full-year revenue is projected at $10.2M, growing to $11.2M next year.
Have analysts been upgrading or downgrading MGX lately?+
As of Jul, 3 of 3 firms rate MGX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MGX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
